NZ712691A - C. novyi for the treatment of solid tumors in humans - Google Patents
C. novyi for the treatment of solid tumors in humansInfo
- Publication number
- NZ712691A NZ712691A NZ712691A NZ71269114A NZ712691A NZ 712691 A NZ712691 A NZ 712691A NZ 712691 A NZ712691 A NZ 712691A NZ 71269114 A NZ71269114 A NZ 71269114A NZ 712691 A NZ712691 A NZ 712691A
- Authority
- NZ
- New Zealand
- Prior art keywords
- human
- novyi
- methods
- solid tumor
- present
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 6
- 241000186581 Clostridium novyi Species 0.000 title abstract 3
- 230000000694 effects Effects 0.000 abstract 3
- 241000530936 Clostridium novyi NT Species 0.000 abstract 2
- 230000001332 colony forming effect Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Reproductive Health (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361806497P | 2013-03-29 | 2013-03-29 | |
| PCT/US2014/032196 WO2014160950A1 (en) | 2013-03-29 | 2014-03-28 | C. novyi for the treatment of solid tumors in humans |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ712691A true NZ712691A (en) | 2020-01-31 |
Family
ID=51625539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ712691A NZ712691A (en) | 2013-03-29 | 2014-03-28 | C. novyi for the treatment of solid tumors in humans |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10617723B2 (enExample) |
| EP (4) | EP4108248B1 (enExample) |
| JP (6) | JP6756609B2 (enExample) |
| KR (1) | KR20160021084A (enExample) |
| CN (2) | CN116570628A (enExample) |
| AU (2) | AU2014240872A1 (enExample) |
| BR (2) | BR112015024621B1 (enExample) |
| CA (2) | CA2908508C (enExample) |
| DK (1) | DK2988760T3 (enExample) |
| ES (3) | ES2815564T3 (enExample) |
| HK (1) | HK1222134A1 (enExample) |
| IL (1) | IL241823B (enExample) |
| MX (1) | MX377118B (enExample) |
| NZ (1) | NZ712691A (enExample) |
| PH (1) | PH12015502260B1 (enExample) |
| RU (1) | RU2718670C2 (enExample) |
| SG (2) | SG11201508071VA (enExample) |
| UA (1) | UA120036C2 (enExample) |
| WO (1) | WO2014160950A1 (enExample) |
| ZA (2) | ZA201507412B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015240884B2 (en) * | 2014-03-31 | 2020-06-18 | Biomed Valley Discoveries, Inc. | Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies |
| CN105912930B (zh) * | 2016-04-11 | 2019-02-01 | 北京奇虎科技有限公司 | 移动终端及其系统资源安全控制方法 |
| WO2018039185A1 (en) * | 2016-08-23 | 2018-03-01 | Mayo Foundation For Medical Education And Research | Methods and materials for treating estrogen receptor positive breast cancer |
| CN110799245B (zh) * | 2017-05-16 | 2022-08-09 | 生物医学谷探索股份有限公司 | 用于治疗具有非典型braf突变的癌症的组合物和方法 |
| CN109985039A (zh) * | 2017-12-29 | 2019-07-09 | 深圳微芯生物科技股份有限公司 | 用于治疗白血病的联合用药物及其在制备用于治疗急性髓性白血病的药物中的用途 |
| WO2021231611A1 (en) * | 2020-05-12 | 2021-11-18 | Splash Pharmaceuticals, Inc. | Methods for treating cancer using spl-108 polypeptide based on tp53 mutational status |
| US11717787B2 (en) | 2021-01-04 | 2023-08-08 | Saudi Arabian Oil Company | High free volume membrane for gas separation |
| CN116917009A (zh) | 2021-02-19 | 2023-10-20 | 美国迈胜医疗系统有限公司 | 用于粒子治疗系统的机架 |
| CN113855710B (zh) * | 2021-10-09 | 2024-02-20 | 施慧达药业集团(吉林)有限公司 | 戈氏梭菌联合肿瘤血管生成抑制剂的应用 |
| CN115350145A (zh) * | 2022-09-06 | 2022-11-18 | 华中科技大学同济医学院附属协和医院 | 细菌介导负载二甲双胍的多肽水凝胶在肿瘤免疫治疗中的应用 |
| WO2025163852A1 (ja) * | 2024-02-01 | 2025-08-07 | ミヤリサン製薬株式会社 | Ｃｄ４－ｃｄ８－ｔ細胞を増殖および／または活性化させるための組成物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4599331A (en) | 1984-12-24 | 1986-07-08 | Syntex (U.S.A.) Inc. | Etianic acids as antiangiogenics |
| EP0245357B1 (en) | 1985-10-23 | 1991-08-07 | The Upjohn Company | Angiostatic steroids |
| US4771042A (en) | 1985-11-25 | 1988-09-13 | The Upjohn Company | Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments |
| EP0477195A1 (en) | 1989-06-16 | 1992-04-01 | The Upjohn Company | Suramin type compounds and angiostatic steroids to inhibit angiogenesis |
| AU678961B2 (en) | 1991-11-22 | 1997-06-19 | Alcon Laboratories, Inc. | Angiostatic steroids |
| WO2002067796A1 (en) | 2001-02-28 | 2002-09-06 | Rex Medical, L.P. | Apparatus for delivering ablation fluid to treat neoplasms |
| DK1446012T3 (da) | 2001-11-21 | 2013-10-14 | Univ Johns Hopkins | Bakteriolytisk kombinationsterapi til behandling af tumorer |
| WO2005018332A1 (en) * | 2003-08-13 | 2005-03-03 | The General Hospital Corporation | Modified microorganisms for anti-cancer therapy |
| ATE459364T1 (de) | 2003-10-22 | 2010-03-15 | Univ Johns Hopkins | Verbesserte bakteriolyse-kombinationstherapie für die behandlung von tumoren |
| US20070015738A1 (en) * | 2005-07-15 | 2007-01-18 | Walker Stephen G | Use of non-antibacterial tetracycline formulations for inhibiting bacterial spores from becoming infectious vegetative cells |
| TW200819540A (en) * | 2006-07-11 | 2008-05-01 | Genelux Corp | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders |
| US9163091B2 (en) * | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
-
2014
- 2014-03-28 SG SG11201508071VA patent/SG11201508071VA/en unknown
- 2014-03-28 US US14/781,273 patent/US10617723B2/en active Active
- 2014-03-28 EP EP22171112.0A patent/EP4108248B1/en active Active
- 2014-03-28 CN CN202310166182.9A patent/CN116570628A/zh active Pending
- 2014-03-28 NZ NZ712691A patent/NZ712691A/en unknown
- 2014-03-28 EP EP14774988.1A patent/EP2988760B1/en active Active
- 2014-03-28 ES ES14774988T patent/ES2815564T3/es active Active
- 2014-03-28 EP EP20167187.2A patent/EP3730146B1/en active Active
- 2014-03-28 AU AU2014240872A patent/AU2014240872A1/en not_active Abandoned
- 2014-03-28 KR KR1020157031284A patent/KR20160021084A/ko not_active Ceased
- 2014-03-28 WO PCT/US2014/032196 patent/WO2014160950A1/en not_active Ceased
- 2014-03-28 BR BR112015024621-4A patent/BR112015024621B1/pt active IP Right Grant
- 2014-03-28 SG SG10201902765VA patent/SG10201902765VA/en unknown
- 2014-03-28 UA UAA201510523A patent/UA120036C2/uk unknown
- 2014-03-28 CA CA2908508A patent/CA2908508C/en active Active
- 2014-03-28 HK HK16110438.1A patent/HK1222134A1/zh unknown
- 2014-03-28 CN CN201480028119.8A patent/CN105451750B/zh active Active
- 2014-03-28 DK DK14774988.1T patent/DK2988760T3/da active
- 2014-03-28 CA CA3206655A patent/CA3206655A1/en active Pending
- 2014-03-28 JP JP2016505594A patent/JP6756609B2/ja active Active
- 2014-03-28 PH PH1/2015/502260A patent/PH12015502260B1/en unknown
- 2014-03-28 MX MX2015013784A patent/MX377118B/es active IP Right Grant
- 2014-03-28 ES ES22171112T patent/ES3048113T3/es active Active
- 2014-03-28 BR BR122020006408-0A patent/BR122020006408B1/pt active IP Right Grant
- 2014-03-28 EP EP25202057.3A patent/EP4653054A2/en active Pending
- 2014-03-28 RU RU2015146199A patent/RU2718670C2/ru active
- 2014-03-28 ES ES20167187T patent/ES2922378T3/es active Active
-
2015
- 2015-09-24 IL IL241823A patent/IL241823B/en active IP Right Grant
- 2015-10-06 ZA ZA2015/07412A patent/ZA201507412B/en unknown
-
2017
- 2017-02-14 JP JP2017025263A patent/JP2017088619A/ja active Pending
- 2017-09-21 ZA ZA2017/06402A patent/ZA201706402B/en unknown
-
2018
- 2018-10-26 JP JP2018201792A patent/JP2019011376A/ja active Pending
-
2019
- 2019-01-17 AU AU2019200276A patent/AU2019200276B2/en active Active
-
2020
- 2020-03-31 US US16/836,003 patent/US11439669B2/en active Active
- 2020-06-25 JP JP2020109387A patent/JP7445893B2/ja active Active
-
2021
- 2021-12-09 JP JP2021199949A patent/JP2022022392A/ja active Pending
-
2022
- 2022-08-02 US US17/816,924 patent/US20220378852A1/en active Pending
-
2024
- 2024-03-06 JP JP2024034039A patent/JP7788114B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ712691A (en) | C. novyi for the treatment of solid tumors in humans | |
| SG10201902664RA (en) | Combination therapy for treating cancer | |
| MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
| MX2021004828A (es) | Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia. | |
| WO2016025635A3 (en) | Combination therapy for treating cancer | |
| NZ700759A (en) | Combination therapy for treating cancer | |
| BR112018008503A2 (pt) | método para tratar câncer de pulmão de células pequenas, método para tratar um sujeito, método para selecionar um sujeito com câncer | |
| AU2018341571A8 (en) | Therapeutic methods relating to HSP90 inhibitors | |
| MX2020003719A (es) | Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer. | |
| MX375442B (es) | Un agente terapéutico y un agente mejorador de la permeación intracelular para usarse en el tratamiento de cáncer. | |
| MX2018008427A (es) | Combinaciones anti-cd20 para tratar tumores. | |
| MX363243B (es) | Composiciones para tratar cáncer y usos de dichas composiciones. | |
| PH12016502354A1 (en) | Pharmaceutical composition | |
| SG10201902594QA (en) | Peptidomimetic macrocycles and uses thereof | |
| MX2019008701A (es) | Terapia de combinacion que involucra compuestos macrociclicos de diarilo. | |
| SG10201909199PA (en) | Method for treating cancer | |
| WO2016043874A3 (en) | Combination therapy for treating cancer | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| MX2015010829A (es) | Compuestos terapeuticos y sus usos. | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| MX2020001727A (es) | Terapia de combinacion. | |
| PH12020500666A1 (en) | Pladienolide compounds and their use | |
| MX2016016388A (es) | Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña. | |
| WO2014160967A3 (en) | C. novyi for the treatment of solid tumors in non-human animals | |
| MX2018004112A (es) | Terapia de combinacion racional para el tratamiento de cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAR 2022 BY CPA GLOBAL Effective date: 20210211 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAR 2023 BY CPA GLOBAL Effective date: 20220210 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAR 2024 BY CPA GLOBAL Effective date: 20230210 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAR 2025 BY AJ PARK Effective date: 20240325 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAR 2026 BY AJ PARK Effective date: 20250218 |